BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 23, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Jan. 12, 2021
View Archived Issues
rVSV-deltaG-spike vaccine protects hamsters against SARS-CoV-2 challenge
Read More
Forma begins phase II/III study of FT-4202 in sickle cell disease
Read More
Viralym-M enters phase III for virus-associated hemorrhagic cystitis
Read More
Dyne reports preclinical data from DM1 program
Read More
Chinese investigators divulge EGFR inhibitors
Read More
Nanjing Greepharma patents new ARG1 inhibitors
Read More
Shanghai Institute of Materia Medica discloses PRDX1 inhibitors
Read More
Hawaii Biotech identified new botulinum neurotoxin inhibitors
Read More
DalCor initiates phase II study of dalcetrapib in patients with COVID-19
Read More
Turning Point Therapeutics describes new RET inhibitors
Read More
Antibody protects broadly against flaviviruses, without ADE
Read More
A humanized mouse HIV latency model to test HIV cure strategies
Read More
Promising data presented from global phase III study with valoctocogene roxaparvovec in hemophilia A
Read More
Identification of small-molecule HNC-0014 as a multi-targeted immunotherapy lead compound for HNSCC
Read More
New heterocyclic ring systems as a novel class of brain-penetrating V1A antagonists
Read More
Chipscreen Biosciences submits IND to the NMPA for pivotal phase III study of chiauranib in SCLC
Read More
Leishmania parasites trigger SHP-1, which acts as a negative regulator of antigen cross-presentation
Read More
Axcella provides development updates for its lead candidates
Read More
European Commission approves Roclanda ophthalmic solution
Read More
Promising data presented from phase II study of rifamycin SV-MMX in IBS-D
Read More
Gannex reports phase I data on ASC-41 supporting progression for NASH
Read More
Helsinn begins phase I/II study of oral RET inhibitor TAS-0953 in advanced solid tumors
Read More
CureVac reports NHP data on COVID-19 vaccine candidate CVnCoV
Read More
New trial investigates use of NAC for IPF
Read More